Ursodeoxycholic acid treatment in patients with primary biliary cirrhosis. A Swedish multicentre, double-blind, randomized controlled study

Scandinavian Journal of Gastroenterology

Volumn 32, Issue 2, 1997, Pages 179-186

  Eriksson, L S ^a   Olsson, R ^b   Glauman, H ^b   Prytz, H ^b   Befrits, R ^b   Ryden B O ^b   Einarsson, K ^b   Lindgren, S ^b   Wallerstedt, S ^b   Weden M ^b  

^a SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^b NONE

Author keywords

Bile acids; Histology; Liver function tests; Primary biliary cirrhosis; Ursodeoxycholic acid

Indexed keywords

PLACEBO; URSODEOXYCHOLIC ACID;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DOUBLE BLIND PROCEDURE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; ORAL DRUG ADMINISTRATION; PRIMARY BILIARY CIRRHOSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

EID: 8044244818     PISSN: 00365521     EISSN: None     Source Type: Journal    
DOI: 10.3109/00365529709000190     Document Type: Article

References (36)

1. Wiesner RH, LaRusso NF, Ludwig J, Dickson ER. Comparison of the clinicopathologic features of primary sclerosing cholangitis and primary biliary cirrhosis. Gastroenterology 1985;88:108-14.
2. Kaplan MM. Medical progress: primary biliary cirrhosis. N Engl J Med 1987;316:521-8.
3. Culp KS, Fleming CR, Duffy J, Baldus WP, Dickson ER. Autoimmune associations in primary biliary cirrhosis. Mayo Clin Proc 1982;57:365-70.
4. Roll J, Boyer JL, Barry D, Klatskin G. The prognostic importance of clinical and histological features in asymptomatic and symptomatic primary biliary cirrhosis. N Engl J Med 1983;308:1-7.
5. Neuberger J, Christensen E, Portman B, Caballeria J, Rodes J, Ranek L, et al. Double-blind controlled trail of d-penicillamine in patients with primary biliary cirrhosis. Gut 1985;26:114-9.
6. Bodenheimer HC, Schaffner F, Sternlieb I, Klion FM, Vernale S, Pezzullo J. A prospective clinical trial of penicillamine in the treatment of primary biliary cirrhosis. Hepatology 1985;5:1139-42.
7. Christensen E, Neuberger J, Crowe J, Altman DG, Popper H, Portman B, et al. Beneficial effect of azathioprine and prediction of prognosis in primary biliary cirrhosis. Gastroenterology 1985;89:1084-90.
8. Zifroni A, Schaffner F. Long-term follow-up of patients with primary biliary cirrhosis on colchicine therapy. Hepatology 1991;14:990-3.
9. Bachrach WH, Hofmann AF. Ursodeoxycholic acid in the treatment of cholesterol cholelithiasis. II. Dig Dis Sci 1982;27:833-56.
10. Calmus Y, Gane P, Rouger P, Poupon R. Hepatic expression of class I and class II major histocompatibility complex molecules in primary biliary cirrhosis: effect of ursodeoxycholic acid. Hepatology 1990;11:12-3.
11. Keane RM, Gadacz TR, Munster AM, Birmingham W, Winchurch RA. Impairment of human lymphocyte function by bile salts. Surgery 1984;95:439-43.
12. Galle PR, Theilmann L, Raedsch R, Otto G, Stiehl A. Ursodeoxycholate reduces hepatotoxicity of bile salts in primary human hepatocytes. Hepatology 1990;12:486-91.
13. Poupon R, Poupon RE, Calmus Y, Chretien Y, Ballet F, Darnis F. Is ursodeoxycholic acid an effective treatment for primary biliary cirrhosis? Lancet 1987;1:834-6.
14. Björkhem I, Falk O. Assay of the major bile acids in serum by isotope dilution-mass spectrometry. Scand J Clin Lab Invest 1983;40:163-70.
15. Ewerth S, Angelin B, Einarsson K, Nilsell K, Björkhem I. Serum concentrations of ursodeoxycholic acid in portal venous and systemic venous blood of fasting humans as determined by isotope dilution-mass spectrometry. Gastroenterology 1985;88:126-33.
16. Knodell RG, Ishak KG, Black WC, Chen TS, Craig R, Kaplowitz N, et al. Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology 1981;1:431-5.
17. Reichard O, Glaumann H, Norkrans G, Wejstål R, Frydén A, Schvarcz R, et al. Histological outcome in patients with chronic hepatitis C given a 60-week interferon alfa-2b treatment course. Liver 1994;14:169-74.
18. Mattsson L, Weiland O, Glaumann H. Application of a histological scoring system for assessment of histological outcome in patients with chronic posttransfusion non A-non B hepatitis with or without antibodies to hepatitis C. Liver 1990;10:257-63.
19. Bradley JW. Distribution-free statistical tests. London: Prentice-Hall, 1968:68-86.
20. Odén A, Wedel H. Arguments for Fisher's permutation test. Ann Statistics 1975;3:518-20.
21. Leuschner U, Fischer H, Kurtz W, Güldütuna S, Hübner K, Hellestern A, et al. Ursodeoxycholic acid in primary biliary cirrhosis: results of a controlled double-blind trial. Gastroenterology 1989;97:1268-74.
22. Poupon RE, Balkau B, Eschwège E, Poupon R, UDCA-PBC Study Group. A multicenter, controlled trial of ursodiol for the treatment of primary biliary cirrhosis. N Engl J Med 1991;324:1548-54.
23. Heathcote EJ, Cauch-Dudek K, Walker V, Bailey JR, Blendis LM, Ghent CN, et al. The Canadian multicenter double-blind randomized controlled study of ursodeoxycholic acid in primary biliary cirrhosis. Hepatology 1994;19:1149-56.
24. Combes B, Carithers RL, Maddrey WC, Lin D, McDonald MF, Wheeler DE, et al. A randomized, double-blind, placebo-controlled trial of ursodeoxycholic acid in primary biliary cirrhosis. Hepatology 1995;22:759-66.
25. Turner IB, Myszor M, Mitchison HC, Bennett MK, Burt AD, James OFW. A two-year controlled trial examining the effectiveness of ursodeoxycholic acid in primary biliary cirrhosis. J Gastroenterol Hepatol 1994;9:162-8.
26. Battezzati PM, Podda M, Bianchi FB, Naccarato R, Orlandi F, Surrenti C, et al. Ursodeoxycholic acid for symptomatic primary biliary cirrhosis. J Hepatol 1993;17:332-8.
27. Lindor KD, Dickson ER, Baldus WP, Jorgensen RA, Ludwig J, Murtaug PA, et al. Ursodeoxycholic acid in the treatment of primary biliary cirrhosis. Gastroenterology 1994;106:1284-90.
28. Leuschner U, Güldtüna S, Imhof M, Hübner K, Benjaminov A, Leuschner M. Effects of ursodeoxycholic acid after 4 to 12 years of therapy in early and late stages of primary biliary cirrhosis. J Hepatol 1994;21:624-33.
29. Neuberger JM, Gunson BK, Buckels JAC, Elias E, McMaster P. Referral of patients with primary biliary cirrhosis for liver transplantation. Gut 1990;31:1069-72.
30. Poupon RE, Poupon R, Balkau B, UDCA-PBC Study Group. Ursodiol for the long-term treatment of primary biliary cirrhosis. N Engl J Med 1994;330:1342-7.
31. Heathcote EJ, Lindor KD, Poupon R, Cauch-Dudek K, Dickson ER, Trout R, et al. Combined analysis of French, American and Canadian randomized controlled trials of ursodeoxycholic acid therapy in primary biliary cirrhosis. Gastroenterology 1995;108:A1082.
32. Batta AK, Salen G, Arora R, Shefer S, Tint GS, Abron J, et al. Effect of ursodeoxycholic acid on bile acid metabolism in primary biliary cirrhosis. Hepatology 1989;10:414-9.
33. Stiehl A, Rudolph G, Raedsch R, Möller B, Hopf U, Lotterer E, et al. Ursodeoxycholic acid-induced changes of plasma and urinary bile acids in patients with primary biliary cirrhosis. Hepatology 1990;12:492-7.
34. Podda M, Ghezzi C, Battezzati PM, Bertolini E, Crosignani A, Petroni ML, et al. Effect of different doses of ursodeoxycholic acid in chronic liver disease. Dig Dis Sci 1989;12:59S-65S.
35. Hwang S-J, Chan C-Y, Lee S-D, Wu J-C, Tsay S-H, Lo K-J. Ursodeoxycholic acid in the treatment of primary biliary cirrhosis: a short-term, randomized, double-blind controlled, cross-over study with long-term follow up. J Gastroenterol Hepatol 1993;8:217-23.
36. Vogel W, Kathren H, Judmaier G, Braunsteiner H. Deterioration of primary biliary cirrhosis during treatment with ursodeoxycholic acid. Lancet 1988;1:1163.